Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Lerchbaum, E; .
Androgens and cardiovascular risk.
LABORATORIUMSMEDIZIN. 2012; 36(4): 217-225. Doi: 10.1515/labmed-2011-0028
Web of Science FullText FullText_MUG

Leading authors Med Uni Graz: Lerchbaum Elisabeth
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Testosterone concentrations in men gradually decrease with age. Whether this reduction in androgen levels is a pathological process or a physiological event remains to be determined. The age-related decrease in testosterone levels is, however, frequently accompanied by adverse health consequences including low bone and muscle mass, increased fat mass, type 2 diabetes mellitus and the metabolic syndrome. Moreover, low androgen levels are associated with increased mortality. Testosterone treatment should be performed in men with low androgen levels as well as clinical signs and symptoms of hypogonadism. In premenopausal women, hyperandrogenemia is associated with several cardiovascular risk factors. The most common cause of hyperandrogenemia in women is polycystic ovary syndrome (PCOS). PCOS women are affected by hyperandrogenism, infertility and metabolic disturbances, such as insulin resistance, central obesity and dyslipidemia. Androgen levels decrease with menopausal transition in women. Hyperandrogenemia is associated with insulin resistance and type 2 diabetes in postmenopausal women. Whether this hyperandrogenemia results in increased mortality is, however, less clear. Moreover, the impact of androgen supplementation in postmenopausal women with hypoandrogenemia is open.
Find related publications in this database (Keywords): androgens; cardiovascular risk; hyperandrogenemia; hypogonadism